A Study of Patients With Pure Red Cell Aplasia Associated With Recombinant Human Erythropoietin Treatment

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.52 enrolled

Overview

The purpose of this study is to investigate the relationship of anti-erythropoietin antibodies to the clinical course and outcome of pure red cell aplasia (PRCA) in participants currently or previously treated with recombinant human erythropoietin.

This is a multicenter (study conducted at multiple sites), observational (study in which the investigators/physicians observe the participant's data and measure their outcomes) study. Approximately 150 participants will be enrolled in this study. The study consists of an initial observation phase and extended observation period. An initial observation phase starting at enrollment and ending when 24 months have elapsed since the date of loss of efficacy (LOE), supplemented with retrospective data collection for the period between LOE date and date of enrollment in the study. Participants remaining epoetin alfa (EPO-Ab) positive 24 months after LOE will enter a 2-year extended observation period. Study visits will take place every month during the initial observation phase and data will be collected every 6 months during the extended observation phase. Safety evaluations will include assessment of adverse events, clinical laboratory tests, vital signs, and physical examination which will be monitored throughout the study. The total study duration for each participant will be approximately for 4 years.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Pure Red-cell Aplasia

Interventions

No interventionOTHER

This is an observational study. No medication will be given to the participants. Participants will receive standard-of-care treatment from their individual physicians.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Pure red cell aplasia (PRCA) associated with recombinant human erythropoietin (r-HuEPO) treatment * Anemia unresponsive to r-HuEPO treatment * PRCA associated with erythropoietin treatment followed by a sudden decrease (more than or equal to 2 gram per deciliter within 30 days) in a previously stable hemoglobin level Exclusion criteria: \- Participants who are not fulfilling the inclusion criteria

Locations (21)

Unnamed facility

Santos, Brazil

Unnamed facility

São Paulo, Brazil

Unnamed facility

Saskatoon, Saskatchewan, Canada

Outcomes

Primary Outcomes

Number of participants with Pure Red Cell Aplasia (PRCA) outcome (Initial observation phase)

The PRCA outcome is measured by anti-epoetin alfa qualitative test. Persistence of PRCA is defined as: 1) absolute reticulocyte count less than 30,000 per cubic millimeter; and/or 2) no reversal of erythroblastopenia on repeated bone marrow testing. Resolution of PRCA is defined as: 1) absolute reticulocyte count greater than or equal to 30,000 per cubic millimeter; and/or 2) reversal of erythroblastopenia on repeated bone marrow testing.

Time frame: Up to 24 months after the date of loss of efficacy

Number of participants with pure red cell aplasia outcome (Extended observation phase)

Participants remaining anti-epoetin alfa positive 24 months after loss of efficacy will enter in the extended observation period.

Time frame: Up to 2 years after the enrollment in the extended observation phase

Overall clinical outcome of pure red cell aplasia (Initial observation phase)

The overall clinical outcome is evaluated by anti-epoetin alfa qualitative test. Overall clinical status will be recorded at each visit in the initial and extended observation phases using a categorical scale (improved, same, worsened, death). In case of death, the date and cause of death along with the the date and cause of death will be recorded.

Time frame: Up to 24 months after the date of loss of efficacy

Overall clinical outcome of pure red cell aplasia (Extended observation phase)

Time frame: Up to 2 years after the enrollment in the extended observation phase

Secondary Outcomes

Different treatment modalities with pure red cell aplasia outcome (Initial observation phase)

Time frame: Up to 24 months after the date of loss of efficacy

Different treatment modalities with pure red cell aplasia outcome (Extended observation phase)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.